Exenatide in type 2 diabetes.
Verzegnassi
Federico
F
Chinello
Matteo
M
D015415:Biomarkers / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D002149:Energy Intake; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D007328:Insulin / Q000031:analogs & derivatives / Q000494:pharmacology; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D011788:Quality of Life; D014688:Venoms / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology
D015415:Biomarkers; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D010455:Peptides; D014688:Venoms; D000069036:Insulin Glargine; D000077270:Exenatide